Literature DB >> 23460154

A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD.

Nausherwan K Burki1, Raj Kumar Mani2, Felix J F Herth3, Werner Schmidt3, Helmut Teschler4, Frank Bonin4, Heinrich Becker5, Winfried J Randerath6, Sven Stieglitz6, Lars Hagmeyer6, Christina Priegnitz6, Michael Pfeifer7, Stefan H Blaas7, Christian Putensen8, Nils Theuerkauf8, Michael Quintel9, Onnen Moerer9.   

Abstract

BACKGROUND: Hypercapnic respiratory failure in patients with COPD frequently requires mechanical ventilatory support. Extracorporeal CO2 removal (ECCO2R) techniques have not been systematically evaluated in these patients.
METHODS: This is a pilot study of a novel ECCO2R device that utilizes a single venous catheter with high CO2 removal rates at low blood flows. Twenty hypercapnic patients with COPD received ECCO2R. Group 1 (n = 7) consisted of patients receiving noninvasive ventilation with a high likelihood of requiring invasive ventilation, group 2 (n = 2) consisted of patients who could not be weaned from noninvasive ventilation, and group 3 (n = 11) consisted of patients on invasive ventilation who had failed attempts to wean.
RESULTS: The device was well tolerated, with complications and rates similar to those seen with central venous catheterization. Blood flow through the system was 430.5 ± 73.7 mL/min, and ECCO2R was 82.5 ± 15.6 mL/min and did not change significantly with time. Invasive ventilation was avoided in all patients in group 1 and both patients in group 2 were weaned; PaCO2 decreased significantly (P < .003) with application of the device from 78.9 ± 16.8 mm Hg to 65.9 ± 11.5 mm Hg. In group 3, three patients were weaned, while the level of invasive ventilatory support was reduced in three patients. One patient in group 3 died due to a retroperitoneal bleed following catheterization.
CONCLUSIONS: This single-catheter, low-flow ECCO2R system provided clinically useful levels of CO2 removal in these patients with COPD. The system appears to be a potentially valuable additional modality for the treatment of hypercapnic respiratory failure.

Entities:  

Mesh:

Year:  2013        PMID: 23460154      PMCID: PMC3590884          DOI: 10.1378/chest.12-0228

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Hypercapnic respiratory failure in COPD patients: response to therapy.

Authors:  G W Hoo; N Hakimian; S M Santiago
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

2.  Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure.

Authors:  L Gattinoni; A Pesenti; D Mascheroni; R Marcolin; R Fumagalli; F Rossi; G Iapichino; G Romagnoli; L Uziel; A Agostoni
Journal:  JAMA       Date:  1986-08-15       Impact factor: 56.272

3.  Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008.

Authors:  Divay Chandra; Jason A Stamm; Brian Taylor; Rose Mary Ramos; Lewis Satterwhite; Jerry A Krishnan; David Mannino; Frank C Sciurba; Fernando Holguín
Journal:  Am J Respir Crit Care Med       Date:  2011-10-20       Impact factor: 21.405

4.  Is extracorporeal CO2 removal an option in the treatment of adult respiratory distress syndrome?

Authors:  J Deslauriers; J A Awad
Journal:  Ann Thorac Surg       Date:  1997-12       Impact factor: 4.330

5.  Dyspnea: mechanisms, evaluation and treatment.

Authors:  N K Burki; M J Tobin; A Guz; J T Sharp; R B Banzett; D A Mahler
Journal:  Am Rev Respir Dis       Date:  1988-10

6.  Determinants of weaning and survival among patients with COPD who require mechanical ventilation for acute respiratory failure.

Authors:  R Menzies; W Gibbons; P Goldberg
Journal:  Chest       Date:  1989-02       Impact factor: 9.410

7.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)

Authors:  A F Connors; N V Dawson; C Thomas; F E Harrell; N Desbiens; W J Fulkerson; P Kussin; P Bellamy; L Goldman; W A Knaus
Journal:  Am J Respir Crit Care Med       Date:  1996-10       Impact factor: 21.405

8.  Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome.

Authors:  A H Morris; C J Wallace; R L Menlove; T P Clemmer; J F Orme; L K Weaver; N C Dean; F Thomas; T D East; N L Pace; M R Suchyta; E Beck; M Bombino; D F Sittig; S Böhm; B Hoffmann; H Becks; S Butler; J Pearl; B Rasmusson
Journal:  Am J Respir Crit Care Med       Date:  1994-02       Impact factor: 21.405

9.  Treatment of acute respiratory failure with low-frequency positive-pressure ventilation and extracorporeal removal of CO2.

Authors:  L Gattinoni; A Agostoni; A Pesenti; A Pelizzola; G P Rossi; M Langer; S Vesconi; L Uziel; U Fox; F Longoni; T Kolobow; G Damia
Journal:  Lancet       Date:  1980-08-09       Impact factor: 79.321

10.  Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy.

Authors:  C B Cooper; J Waterhouse; P Howard
Journal:  Thorax       Date:  1987-02       Impact factor: 9.139

View more
  57 in total

1.  What's new in extracorporeal carbon dioxide removal for COPD?

Authors:  Darryl Abrams; Roberto Roncon-Albuquerque; Daniel Brodie
Journal:  Intensive Care Med       Date:  2015-02-03       Impact factor: 17.440

2.  Low-Flow Extracorporeal Carbon Dioxide Removal Using the Hemolung Respiratory Dialysis System® to Facilitate Lung-Protective Mechanical Ventilation in Acute Respiratory Distress Syndrome.

Authors:  Bindu Akkanti; Keshava Rajagopal; Kirti P Patel; Sangeeta Aravind; Emmanuel Nunez-Centanu; Rahat Hussain; Farshad Raissi Shabari; Wayne L Hofstetter; Ara A Vaporciyan; Igor S Banjac; Biswajit Kar; Igor D Gregoric; Pranav Loyalka
Journal:  J Extra Corpor Technol       Date:  2017-06

Review 3.  Spontaneous breathing during veno-venous extracorporeal membrane oxygenation.

Authors:  Stefania Crotti; Nicola Bottino; Elena Spinelli
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 4.  Ventilator Support and Oxygen Therapy in Palliative and End-of-Life Care in the Elderly.

Authors:  Raffaele Scala; Giuseppina Ciarleglio; Uberto Maccari; Valentina Granese; Laura Salerno; Chiara Madioni
Journal:  Turk Thorac J       Date:  2020-01-01

Review 5.  [Extracorporeal pulmonary support procedures in intensive care medicine 2014].

Authors:  T Müller; M Lubnow; A Philipp; M Pfeifer; L S Maier
Journal:  Internist (Berl)       Date:  2014-11       Impact factor: 0.743

Review 6.  [Extracorporeal lung support].

Authors:  S Braune; A Sieweke; D Jarczak; S Kluge
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-29       Impact factor: 0.840

Review 7.  Mechanical ventilation and respiratory monitoring during extracorporeal membrane oxygenation for respiratory support.

Authors:  Nicolò Patroniti; Giulia Bonatti; Tarek Senussi; Chiara Robba
Journal:  Ann Transl Med       Date:  2018-10

Review 8.  [Extracorporeal membrane oxygenation : System selection, (contra)indications, and management].

Authors:  T Staudinger
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05       Impact factor: 0.840

Review 9.  Extracorporeal carbon dioxide removal (ECCO2R) in respiratory deficiency and current investigations on its improvement: a review.

Authors:  Hany Hazfiza Manap; Ahmad Khairi Abdul Wahab
Journal:  J Artif Organs       Date:  2016-05-18       Impact factor: 1.731

10.  The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to noninvasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study.

Authors:  Stephan Braune; Annekatrin Sieweke; Franz Brettner; Thomas Staudinger; Michael Joannidis; Serge Verbrugge; Daniel Frings; Axel Nierhaus; Karl Wegscheider; Stefan Kluge
Journal:  Intensive Care Med       Date:  2016-07-25       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.